Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Reverse Transcriptase Inhibitors"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 477
Tytuł:
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
Autorzy:
Shafran SD; Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Hughes CA; Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2023 Mar; Vol. 24 (3), pp. 361-365. Date of Electronic Publication: 2022 Aug 16.
Typ publikacji:
Journal Article
MeSH Terms:
HIV Infections*/drug therapy
HIV Infections*/genetics
Humans ; Male ; Female ; Middle Aged ; Genotype ; HIV-1 ; Anti-Retroviral Agents ; Drug Resistance, Viral ; Viral Load ; Reverse Transcriptase Inhibitors/therapeutic use ; HIV Reverse Transcriptase/antagonists & inhibitors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV.
Autorzy:
Garcia JM; Geriatric Research, Education and Clinical Center (GRECC), VA Puget Sound Health Care System, and Department of Medicine, Division of Gerontology & Geriatric Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Dong Y; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
Richardson P; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
Kramer JR; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.; Texas Medical Center Digestive Diseases Center, Baylor College of Medicine, Houston, Texas, USA.; Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, USA.; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Hartman CM; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.
Royse K; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.; Surgical Outcomes and Analysis, Kaiser Permanente, San Diego, California, USA.
White DL; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.; Texas Medical Center Digestive Diseases Center, Baylor College of Medicine, Houston, Texas, USA.; Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, USA.; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.; Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Chiao EY; VA Health Services Research Center of Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, Texas, USA.; Department of General Oncology and Epidemiology, Division of Cancer Medicine and Cancer Prevention, University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2023 Feb; Vol. 24 (2), pp. 180-190. Date of Electronic Publication: 2022 Aug 05.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
HIV Infections*/complications
HIV Infections*/drug therapy
Veterans*
Anti-HIV Agents*/therapeutic use
Humans ; Middle Aged ; Retrospective Studies ; Body Weight ; Obesity/complications ; Obesity/epidemiology ; Weight Gain ; Reverse Transcriptase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Autorzy:
Mocroft A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
Neesgard B; Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Zangerle R; Medical University of Innsbruck, Innsbruch, Austria.
Rieger A; Medical University of Vienna, Vienna, Austria.
Castagna A; Vita-Salute San Raffaele University, Milano, Italy.
Spagnuolo V; Vita-Salute San Raffaele University, Milano, Italy.
Antinori A; Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy.
Lampe FC; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
Youle M; Royal Free Hospital, London, UK.
Vehreschild JJ; University Hospital Cologne, Cologne, Germany.
Mussini C; University of Modena, Modena, Italy.
Borghi V; University of Modena, Modena, Italy.
Begovac J; University Hospital of Infectious Diseases, Zagreb, Croatia.
Duvivier C; Necker University Hospital, Department of Infectious and Tropical Diseases, Paris, France.
Gunthard HF; University of Zurich, Zurich, Switzerland.; University Hospital of Zurich, Zurich, Switzerland.
Rauch A; University Hospital Berne, Bern, Switzerland.
Tiraboschi J; PISCIS Cohort Study, Bellvitge Hospital, Barcelona, Spain.
Chkhartishvili N; PISCIS Cohort Study, Bellvitge Hospital, Barcelona, Spain.
Bolokadze N; Georgian National AIDS Health Information System (AIDS HIS), Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
Wit F; Stichting HIV Monitoring (SHM), Amsterdam, the Netherlands.
Wasmuth JC; University Hospital Bonn, Bonn, Germany.
De Wit S; Infectious Disease Research Centre, Brussels, Belgium.
Necsoi C; Infectious Disease Research Centre, Brussels, Belgium.
Pradier C; Côte d'Azur University and University Hospital Center, Nice, France.
Svedhem V; Karolinska University Hospital, Stockholm, Sweden.
Stephan C; Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany.
Petoumenos K; Kirby Institute, New South Wales, Australia.
Garges H; ViiV Healthcare, London, UK.
Rogatto F; Gilead Sciences, Foster City, CA, USA.
Peters L; Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Ryom L; Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Corporate Authors:
RESPOND study group
Źródło:
HIV medicine [HIV Med] 2020 Oct; Vol. 21 (9), pp. 599-606. Date of Electronic Publication: 2020 Jun 26.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*therapeutic use
HIV-1/*genetics
Protease Inhibitors/*therapeutic use
Reverse Transcriptase Inhibitors/*therapeutic use
Adult ; CD4 Lymphocyte Count ; Cohort Studies ; Female ; HIV Infections/immunology ; HIV Infections/virology ; HIV Integrase Inhibitors/pharmacology ; HIV-1/drug effects ; Humans ; International Cooperation ; Logistic Models ; Male ; Middle Aged ; Protease Inhibitors/pharmacology ; RNA, Viral/drug effects ; Reverse Transcriptase Inhibitors/pharmacology ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Autorzy:
Mwasakifwa GE; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Amin J; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.; Department of Health Systems and Populations, Macquarie University, Sydney, NSW, Australia.
White CP; Department of Endocrinology, Prince of Wales Hospital, Sydney, NSW, Australia.
Center JR; The Garvan Institute of Medical Research, Sydney, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Kelleher A; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
Boyd MA; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2020 Sep; Vol. 21 (8), pp. 492-504. Date of Electronic Publication: 2020 Jun 23.
Typ publikacji:
Clinical Study; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers/*metabolism
HIV Infections/*drug therapy
Hip/*diagnostic imaging
Raltegravir Potassium/*administration & dosage
Reverse Transcriptase Inhibitors/*administration & dosage
Spine/*diagnostic imaging
Tenofovir/*administration & dosage
Absorptiometry, Photon ; Adult ; Bone Density/drug effects ; C-Reactive Protein/metabolism ; CD4 Lymphocyte Count ; Female ; HIV Infections/diagnostic imaging ; HIV Infections/immunology ; HIV-1/drug effects ; HIV-1/physiology ; Humans ; Interleukin-6/metabolism ; Male ; Middle Aged ; Neopterin/metabolism ; Peptide Fragments/metabolism ; Procollagen/metabolism ; Raltegravir Potassium/adverse effects ; Random Allocation ; Reverse Transcriptase Inhibitors/adverse effects ; Spine/drug effects ; Tenofovir/adverse effects ; Treatment Failure ; Treatment Outcome ; Tumor Necrosis Factor-alpha/metabolism ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population-based cohort study.
Autorzy:
Moseholm E; Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.; Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Katzenstein TL; Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Pedersen G; Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark.
Johansen IS; Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Wienecke LS; Midwifery Programme, University College Copenhagen, Copenhagen, Denmark.
Storgaard M; Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
Obel N; Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Weis N; Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Oct; Vol. 23 (9), pp. 1007-1018. Date of Electronic Publication: 2022 Apr 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*/complications
HIV Infections*/drug therapy
Pregnancy Complications, Infectious*/drug therapy
Premature Birth*/epidemiology
Cohort Studies ; Denmark/epidemiology ; Female ; Humans ; Infant, Newborn ; Pregnancy ; Pregnancy Outcome/epidemiology ; RNA/therapeutic use ; Reverse Transcriptase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
Autorzy:
Álvarez H; Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, A Coruña, Spain.; Universidade de Vigo, Vigo, Spain.
Rava M; AIDS Research Network Cohort (CoRIS), National Center of Epidemiology (CNE), Health Institute Carlos III (ISCIII), Madrid, Spain.
Martínez C; Methodology and Statistics Unit, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain.
Portilla J; Hospital General Universitario de Alicante, Alicante, Spain.
Peraire J; Hospital Universitari de Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain.
Rivero A; Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.; CIBERINFEC, Madrid, Spain.
Cervero M; Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain.
Mariño A; Infectious Diseases Unit, Department of Internal Medicine, University Hospital of Ferrol, A Coruña, Spain.
Poveda E; Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (IIS Galicia Sur)-Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain.
Llibre JM; Infectious Diseases and 'Fight AIDS and Infectious Diseases' Foundation, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Pokaż więcej
Corporate Authors:
CoRIS Study Group
Źródło:
HIV medicine [HIV Med] 2022 Sep; Vol. 23 (8), pp. 825-836. Date of Electronic Publication: 2022 Mar 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Integrase Inhibitors*/therapeutic use
HIV-1*
Adult ; Anti-Retroviral Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Humans ; Integrase Inhibitors/therapeutic use ; RNA/therapeutic use ; Reverse Transcriptase Inhibitors/therapeutic use ; Viral Load ; Viremia/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Autorzy:
Byonanebye DM; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.; School of Public Health, Makerere University, Kampala, Uganda.
Polizzotto MN; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Neesgaard B; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Sarcletti M; Department of Dermatology, Venerology and Allergology, Medical University Innsbruck, Innsbruck, Austria.
Matulionyte R; Department of Infectious Diseases and Dermatovenerology, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
Braun DL; Division of Infectious Diseases and Hospital Epidemiology, Switzerland Swiss HIV Cohort Study (SHCS), Institute of Medical Virology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Castagna A; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy.
de Wit S; CHU Saint Pierre, Infectious Diseases, Université Libre de Bruxelles, Brussels, Belgium.
Wit F; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands.
Fontas E; Nice HIV Cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France.
Vehreschild JJ; Medical Department 2, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany.; Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Vesterbacka J; Swedish InfCare HIV Cohort, Karolinska University Hospital, Huddinge, Sweden.
Greenberg L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
Hatleberg C; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Garges H; ViiV Healthcare, RTP, North Carolina, USA.
Gallant J; Gilead Sciences, Foster City, California, USA.
Volny Anne A; EATG European AIDS Treatment Group, Brussels, Belgium.
Öllinger A; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Mozer-Lisewska I; Poznan University of Medical Sciences, Poznan, Poland.
Surial B; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Spagnuolo V; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy.
Necsoi C; CHU Saint Pierre, Infectious Diseases, Université Libre de Bruxelles, Brussels, Belgium.
van der Valk M; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands.; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Mocroft A; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
Law M; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Ryom L; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Petoumenos K; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
Pokaż więcej
Corporate Authors:
RESPOND study group
Źródło:
HIV medicine [HIV Med] 2022 Sep; Vol. 23 (8), pp. 895-910. Date of Electronic Publication: 2022 Mar 01.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Anti-HIV Agents*/adverse effects
HIV Infections*/complications
HIV Infections*/drug therapy
HIV Integrase Inhibitors*/adverse effects
Hypertension*/chemically induced
Hypertension*/epidemiology
Adolescent ; Adult ; Aged, 80 and over ; Anti-Retroviral Agents/therapeutic use ; Humans ; Incidence ; Integrase Inhibitors/therapeutic use ; Reverse Transcriptase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pre-treatment and acquired antiretroviral drug resistance among people living with HIV in Tianjin, China.
Autorzy:
Gao L; Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.
Xia H; Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.; Tianjin Association of STD/AIDS Prevention and Control, Tianjin, China.
Zeng R; Department of Infectious Diseases, Nanjing Lishui People's Hospital, Nanjing, Jiangsu, China.
Wu Y; Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.
Zaongo SD; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.; College of Basic Medicine, Chongqing Medical University, Chongqing, China.
Hu Y; Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.
Ma P; Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.; Tianjin Association of STD/AIDS Prevention and Control, Tianjin, China.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Mar; Vol. 23 Suppl 1, pp. 84-94.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
HIV-1*
Anti-Retroviral Agents/pharmacology ; Anti-Retroviral Agents/therapeutic use ; Drug Resistance, Viral/genetics ; Genotype ; Humans ; Mutation ; Reverse Transcriptase Inhibitors/pharmacology ; Reverse Transcriptase Inhibitors/therapeutic use ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Autorzy:
Lakatos B; HIV Center, National Institute of Hematology and Infectious Diseases, South Pest Central Hospital, Budapest, Hungary.
Kowalska J; Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
Antoniak S; Viral Hepatitis and AIDS Department at the Gromashevsky Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine.
Gokengin D; Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, Izmir, Turkey.
Begovac J; School of Medicine, University Hospital for Infectious Diseases, University of Zagreb, Zagreb, Croatia.
Vassilenko A; Global Fund Grant Management Department, Republican Scientific and Practical Center for Medical Technologies, Minsk, Belarus.
Wasilewski P; 4th Department, Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.
Fleischhans L; Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka, Bulovka, Czech Republic.
Jilich D; Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka, Bulovka, Czech Republic.
Matulionyte R; Faculty of Medicine, Vilnius University, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Kase K; West Tallinn Central Hospital, Tallinn, Estonia.
Papadopoulus A; Medical School, National and Kapodistrian University of Athens, University General Hospital Attikon, Athens, Greece.
Rukhadze N; Infectious Diseases, AIDS and Clinical Immunology Center, Tbilisi, Georgia.
Harxhi A; Infectious Disease Service, University Hospital Center of Tirana, Tirana, Albania.
Hofman S; Faculty of Medicine in Plzeň, Charles University, University Hospital Plzeň, Plzeň, Czech Republic.
Dragovic G; Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia.
Vasyliev M; Astar Medical Center, Lviv, Ukraine.
Verhaz A; Department for Infectious Diseases, Faculty of Medicine, University of Banja Luka, Republika Srpska, Banja Luka, Bosnia and Herzegovina.
Yancheva N; Department for AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Disease Sofia, Sofi, Bulgaria.
Oprea C; Carol Davila University of Medicine and Pharmacy, Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania.
Pokaż więcej
Corporate Authors:
Euroguideliness in Central and Eastern Europe (ECEE) Network Group
Źródło:
HIV medicine [HIV Med] 2022 Jul; Vol. 23 (6), pp. 693-700. Date of Electronic Publication: 2021 Dec 03.
Typ publikacji:
Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Seropositivity*/drug therapy
COVID-19 Drug Treatment*
Adenine/therapeutic use ; Adult ; Drug Interactions ; Emtricitabine/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Reverse Transcriptase Inhibitors ; SARS-CoV-2 ; Tenofovir/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Similar long-term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV-1-infected patients in a retrospective, real-life cohort of 14 years.
Autorzy:
Krznaric I; Centre for Infectious Diseases, Berlin, Germany.
Bickel M; Infektiologikum (Centre for Infectious Diseases) Frankfurt, Frankfurt, Germany.
Carganico A; Centre for Infectious Diseases, Berlin, Germany.
De Leuw P; Infectious Diseases Division, Department of Internal Medicine II, HIV Center, University Hospital Frankfurt, Frankfurt, Germany.
Haberl A; Infectious Diseases Division, Department of Internal Medicine II, HIV Center, University Hospital Frankfurt, Frankfurt, Germany.
Knecht G; Infektiologikum (Centre for Infectious Diseases) Frankfurt, Frankfurt, Germany.
Koegl C; MUC Research, Munich, Germany.
Lauscher P; MUC Research, Munich, Germany.
Schüttfort G; Infectious Diseases Division, Department of Internal Medicine II, HIV Center, University Hospital Frankfurt, Frankfurt, Germany.
Stephan C; Infectious Diseases Division, Department of Internal Medicine II, HIV Center, University Hospital Frankfurt, Frankfurt, Germany.
Wolf E; MUC Research, Munich, Germany.
Wolf T; Infectious Diseases Division, Department of Internal Medicine II, HIV Center, University Hospital Frankfurt, Frankfurt, Germany.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2018 Oct; Vol. 19 (9), pp. 662-667. Date of Electronic Publication: 2018 Jul 03.
Typ publikacji:
Comparative Study; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections/*drug therapy
HIV-1/*drug effects
Protease Inhibitors/*administration & dosage
Raltegravir Potassium/*administration & dosage
Reverse Transcriptase Inhibitors/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Female ; HIV Infections/virology ; Humans ; Male ; Middle Aged ; Prospective Studies ; Protease Inhibitors/pharmacology ; Raltegravir Potassium/pharmacology ; Reverse Transcriptase Inhibitors/pharmacology ; Sustained Virologic Response ; Treatment Outcome ; Viral Load/drug effects ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Autorzy:
Campbell L; King's College London, London, UK.; King's College Hospital NHS Foundation Trust, London, UK.
Ibrahim F; King's College London, London, UK.
Barbini B; King's College Hospital NHS Foundation Trust, London, UK.
Samarawickrama A; Sexual Health South West London, London, UK.
Orkin C; Queen Mary University of London and Barts Health NHS Trust, London, UK.
Fox J; King's College London, London, UK.; Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK.
Waters L; Mortimer Market Centre, London, UK.
Gilleece Y; University Hospitals Sussex NHS Trust, Brighton, UK.; Brighton & Sussex Medical School, Brighton, UK.
Tariq S; University College London, London, UK.
Post FA; King's College London, London, UK.; King's College Hospital NHS Foundation Trust, London, UK.
Pokaż więcej
Corporate Authors:
BESTT Trial Team*,†
Źródło:
HIV medicine [HIV Med] 2022 Apr; Vol. 23 (4), pp. 362-370. Date of Electronic Publication: 2021 Dec 05.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-HIV Agents*/adverse effects
HIV Infections*/complications
Adult ; Bone Density ; Dideoxynucleosides/therapeutic use ; Drug Combinations ; Emtricitabine/pharmacology ; Emtricitabine/therapeutic use ; Female ; Heterocyclic Compounds, 3-Ring ; Humans ; Kidney ; Lamivudine/pharmacology ; Middle Aged ; Oxazines ; Patient Reported Outcome Measures ; Piperazines ; Pyridones ; Reverse Transcriptase Inhibitors/pharmacology ; Tenofovir/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV.
Autorzy:
Han WM; The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Law MG; The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Choi JY; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Ditangco R; Research Institute for Tropical Medicine, Muntinlupa City, Philippines.
Kumarasamy N; Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHS, Chennai, India.
Chaiwarith R; Chiang Mai University - Research Institute for Health Sciences, Chiang Mai, Thailand.
Ly PS; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
Khusuwan S; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
Merati TP; Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia.
Do CD; Bach Mai Hospital, Hanoi, Vietnam.
Yunihastuti E; Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
Azwa I; University Malaya Medical Centre, Kuala Lumpur, Malaysia.
Lee MP; Queen Elizabeth Hospital, Hong Kong SAR, China.
Pham TN; National Hospital for Tropical Diseases, Hanoi, Vietnam.
Chan YJ; Taipei Veterans General Hospital, Taipei, Taiwan.
Kiertiburanakul S; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Ng OT; Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore.
Tanuma J; National Center for Global Health and Medicine, Tokyo, Japan.
Pujari S; Institute of Infectious Diseases, Pune, India.
Zhang F; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Gani Y; Hospital Sungai Buloh, Sungai Buloh, Malaysia.
Mave V; BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India.
Ross J; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Avihingsanon A; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.; Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pokaż więcej
Corporate Authors:
TREAT Asia HIV Observational Database of IeDEA Asia-Pacific
Źródło:
HIV medicine [HIV Med] 2022 Mar; Vol. 23 (3), pp. 274-286. Date of Electronic Publication: 2021 Nov 23.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
HIV Infections*/complications
HIV Infections*/drug therapy
Metabolic Syndrome*/complications
Metabolic Syndrome*/drug therapy
Metabolic Syndrome*/epidemiology
Adult ; CD4 Lymphocyte Count ; Cohort Studies ; Humans ; Male ; Reverse Transcriptase Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
Autorzy:
Brown JA; Clinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.; Molecular Virology Group, Department of Biomedicine, University of Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Nsakala BL; SolidarMed, Partnerships for Health, Maseru, Lesotho.
Mokhele K; SolidarMed, Partnerships for Health, Maseru, Lesotho.
Rakuoane I; SolidarMed, Partnerships for Health, Maseru, Lesotho.
Muhairwe J; SolidarMed, Partnerships for Health, Maseru, Lesotho.
Urda L; Molecular Virology Group, Department of Biomedicine, University of Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Amstutz A; Clinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland.; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Tschumi N; Clinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Klimkait T; Molecular Virology Group, Department of Biomedicine, University of Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Labhardt ND; Clinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland.; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Mar; Vol. 23 (3), pp. 287-293. Date of Electronic Publication: 2021 Oct 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Cohort Studies ; Female ; Heterocyclic Compounds, 3-Ring ; Humans ; Lesotho ; Male ; Middle Aged ; Oxazines ; Piperazines ; Prospective Studies ; Pyridones ; Reverse Transcriptase Inhibitors/therapeutic use ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
No overall impact on rate of weight gain with integrase inhibitor-containing regimens in antiretroviral-naïve adults.
Autorzy:
Burns JE; Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK.; Central and North West London NHS Foundation Trust, London, UK.
Stirrup O; Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK.
Waters L; Central and North West London NHS Foundation Trust, London, UK.
Dunn D; Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK.; Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Gilson R; Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK.; Central and North West London NHS Foundation Trust, London, UK.
Pett SL; Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK.; Central and North West London NHS Foundation Trust, London, UK.; Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Mar; Vol. 23 (3), pp. 294-300. Date of Electronic Publication: 2021 Oct 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*/drug therapy
HIV Integrase Inhibitors*/adverse effects
Adult ; Humans ; Male ; Retrospective Studies ; Reverse Transcriptase Inhibitors/adverse effects ; Weight Gain
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pretreatment drug resistance in people living with HIV: A large retrospective cohort study in Chongqing, China.
Autorzy:
Liu M; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
He XQ; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Deng RN; Department of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Tang SQ; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Harypursat V; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Lu YQ; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
He K; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Huo Q; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Yang HH; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Liu Q; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.
Chen YK; Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China.; Department of Clinical Laboratory, Chongqing Public Health Medical Center, Chongqing, China.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Mar; Vol. 23 Suppl 1, pp. 95-105.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
China/epidemiology ; Drug Resistance, Viral/genetics ; Female ; Genotype ; Humans ; Mutation ; Prevalence ; Retrospective Studies ; Reverse Transcriptase Inhibitors/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Longitudinal analysis of new-onset non-AIDS-defining diseases among people living with HIV: A real-world observational study.
Autorzy:
Duan Y; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Zhao H; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Tang W; University of North Carolina Project-China, Guangzhou, China.
Chen M; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Liu X; North Carolina State University, Raleigh, North Carolina, USA.
Yang D; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Gao G; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Xiao J; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Han N; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Liang H; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Wu L; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Ni L; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Wang F; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Song Y; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Xie X; Peking University Ditan Teaching Hospital, Beijing, China.
Zhang F; Beijing Ditan Hospital, Capital Medical University, Beijing, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, China.
Pokaż więcej
Źródło:
HIV medicine [HIV Med] 2022 Mar; Vol. 23 Suppl 1, pp. 32-41.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Anti-HIV Agents*/adverse effects
Dyslipidemias*/chemically induced
Dyslipidemias*/epidemiology
HIV Infections*/complications
HIV Infections*/drug therapy
Hypercholesterolemia*/drug therapy
Hypertriglyceridemia*/chemically induced
Hypertriglyceridemia*/drug therapy
Hypertriglyceridemia*/epidemiology
CD4 Lymphocyte Count ; Humans ; RNA/therapeutic use ; Reverse Transcriptase Inhibitors/therapeutic use ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real‐life experience from a French cohort (2019–2023).
Autorzy:
Frange, P.
Veber, F.
Burgard, M.
Blanche, S.
Avettand‐Fenoel, V.
Pokaż więcej
Temat:
HIV infections
HIV integrase inhibitors
GENETIC mutation
VIRAL load
TENOFOVIR
PURINES
DRUG resistance
RETROSPECTIVE studies
ACQUISITION of data
TREATMENT failure
RISK assessment
GENOTYPES
MEDICAL records
DRUGS
PATIENT compliance
EMTRICITABINE
FRENCH people
NUCLEOSIDE reverse transcriptase inhibitors
CHILDREN
ADOLESCENCE
Źródło:
HIV Medicine; Feb2024, Vol. 25 Issue 2, p299-305, 7p
Czasopismo naukowe
Szczegóły
Tytuł:
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Autorzy:
Pett SL; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.; Institutes of Clinical Trials and Methodology, University College London, London, UK.; Clinical Research Group, Infection and Population Health, Institute for Global Health, University College London, London, UK.
Amin J; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Horban A; Wojewodzki Szpital Zakazny Centre for AIDS therapy and Diagnosis, Warsaw, Poland.
Andrade-Villanueva J; Hospital Civil de Guadalajara 'Fray Antonio Alcalde', Jalisco, Mexico.
Losso M; Hospital General de Agudos J M Ramos Mejia, Buenos Aires, Argentina.; Fundación IBIS CICAL, Buenos Aires, Argentina.
Porteiro N; Fundación IDEAA, Buenos Aires, Argentina.
Madero JS; Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran, Tlalpan, Mexico.
Belloso W; Fundación IBIS CICAL, Buenos Aires, Argentina.; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Tu E; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Silk D; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
Kelleher A; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.; St Vincent's Hospital, Sydney, NSW, Australia.
Harrigan R; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada.
Clark A; ViiV Healthcare Ltd, London, UK.
Sugiura W; Nagoya Medical Centre, Nagoya, Japan.
Wolff M; Fundacion Arriaran, Santiago, Chile.
Gill J; Southern Alberta Clinic, Calgary, AB, Canada.
Gatell J; Hospital Clinic de Barcelona, Barcelona, Spain.
Clarke A; Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.
Ruxrungtham K; HIV-NAT, Thai Red Cross AIDS Research Center.; Chulalongkorn University, Bangkok, Thailand.
Prazuck T; Orleans Hospital (CHR Orleans La Source), Orleans, France.
Kaiser R; Institut für Virologie, Cologne, Germany.
Woolley I; Monash Medical Centre and Monash University, Melbourne, Vic, Australia.
Alberto Arnaiz J; Fundacion Clinic Spain CTU, Barcelona, Spain.
Cooper D; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.; St Vincent's Hospital, Sydney, NSW, Australia.
Rockstroh JK; Department of Medicine I, University Hospital Bonn, Bonn, Germany.
Mallon P; School of Medicine, University College Dublin, Dublin, Ireland.
Emery S; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.; Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia.
Pokaż więcej
Corporate Authors:
MARCH study group
Źródło:
HIV medicine [HIV Med] 2018 Jan; Vol. 19 (1), pp. 65-71. Date of Electronic Publication: 2017 Jul 13.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Drug Substitution*
Antiretroviral Therapy, Highly Active/*methods
CCR5 Receptor Antagonists/*administration & dosage
Cyclohexanes/*administration & dosage
HIV Infections/*drug therapy
HIV Protease Inhibitors/*administration & dosage
Reverse Transcriptase Inhibitors/*administration & dosage
Triazoles/*administration & dosage
Adult ; Antiretroviral Therapy, Highly Active/adverse effects ; CCR5 Receptor Antagonists/adverse effects ; Cyclohexanes/adverse effects ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; HIV Protease Inhibitors/adverse effects ; HIV-1/isolation & purification ; Humans ; Maraviroc ; RNA, Viral/blood ; Reverse Transcriptase Inhibitors/adverse effects ; Treatment Outcome ; Triazoles/adverse effects ; Viral Load
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 477

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies